#59 Transitional Cannabis Research and Clinical Trials

#61 How Cannabis Can Be Effective for Cancer Pain

Today's guest is Dr. Brooke Worster a Cancer Pain Management Doctor at Jefferson Health in Philadelphia and a cannabis researcher with Thomas Jefferson University. Her research interests focus on improving the quality of life for patients with serious illnesses. 

This includes both the impact, risks, and benefits of cannabis compared to other prescription pharmacotherapy for pain and other burdensome symptoms as well as how to quantify and maximize the benefits of team-based interprofessional interactions for patients and their families. 

#60 How Lumenate Is the App "Tat Makes You Trip"

Lumenate is a pioneering app that uses sound and light to change brain rhythms in ways similar to psychedelics and highly experienced meditators, and brain imaging researchers at Imperial College London and as well as researchers in Berlin. 

Our guests have talked about what psychedelic experiences and Lumenate appear to have in common. They talked about Increased brain signal complexity, reduced activity in the default mode network, increased functional connectivity between different brain regions, and reductions in peak alpha brainwaves. 

They have ongoing trials underway in London which "aims to uncover neural mechanisms of visual imagery induced by Lumenate, using high-density EEG. The research also aims at comparing psychedelic experiences induced by DMT and Lumenate, by exploring the psychological and biological mechanisms of both altered states of consciousness”.

#59 Transitional Cannabis Research and Clinical Trials

Dr. Cornblatt is a Johns Hopkins University School of Medicine Graduate with a Ph.D. in Pharmacology and Molecular Sciences and a postdoctoral fellowship from the Johns Hopkins Bloomberg School of Public Health, Environmental Health Sciences Division of Toxicology.

Dr. Cornblatt has served as Director of Consumer Clinical Research and Science and as Medical Director at Nutramax Laboratories Consumer Care, Inc. In this role, Dr. Cornblatt developed novel nutraceutical formulations, designed both in vitro and clinical studies in support of products, and summarized both supporting laboratory and clinical research for healthcare workers and consumers.

 His most recent development has been a novel line of products (and 18 related clinical trials) that deliver the essential ingredients needed to support the production of sulforaphane, a phytochemical with many emerging indications. Dr. Cornblatt is also the inventor of three issued patents and four pending provisional patents focused on plant-based bioactive compounds and health promotion.

#58 Psychedelic Treatment over Traditional Therapeutics?

Silo Pharma merges traditional therapeutics with psychedelic research to develop innovative solutions that address a variety of underserved conditions including Alzheimer’s, Fibromyalgia, Parkinson’s, Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), as well as stress-induced psychiatric disorders (i.e. PTSD) and other debilitating chronic conditions. We talk about the research and the conditions you choose to study in conjunction with psychedelic treatment. 

Silo has partnered with several leading academic institutions (the University of California, San Francisco, Columbia University, and the University of Maryland, Baltimore) to facilitate a streamlined regulatory pathway for drug approval. The company has developed a pipeline of proprietary licensed therapeutics that show promise for a range of illnesses and diseases.

Silo Pharma Inc. has begun dosing in its IND-enabling study of a proprietary time-released, topical formulation of ketamine SP-26 designed to treat fibromyalgia. The safety evaluation trial will be conducted by Experimur, a Frontage Company, and intends to evaluate the tolerability of SP-26 to establish a maximum dose in the treatment of this chronic medical condition causing widespread musculoskeletal pain as well as memory issues, sleep difficulties, and fatigue.

#57 Psychedelic Integration, Mastering Change and The Shadow Tribe

Steven Twohig has been studying an abundance of practices extensively, including mindfulness, business optimization, shadow work and facilitation, Neuro-Linguistic Programming (NLP), hypnotherapy, and leadership dynamics. He recently has been researching psychedelic integration, which is defined as a process in which the patient integrates the insights of their experience into their life, and PHRI is a method of supporting that in the clinical consultation room.

On Steven's website for Mastering Change, he wrote: “miscoding deep in the human mind. This coding is the root cause of all suffering in the world. By doing your shadow work, you are doing the work necessary to change the world. Everything in this reality is a reflection of everything else. If above, so below. So within, so without. You are a reflection of your outside world, just like this world is a reflection of you.” Steven expands on this and much more in today's episode.